rs1805762 — M6PR

Intronic M6PR variant associated with modest hypertension risk in East Asian populations through lysosomal trafficking and intracellular receptor recycling pathways

See your personal result for M6PR

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

M6PR and Hypertension Risk — A Lysosomal Trafficking Gene Enters the Blood Pressure Story

The M6PR gene encodes the cation-dependent mannose-6-phosphate receptor (CD-M6PR)11 cation-dependent mannose-6-phosphate receptor (CD-M6PR)
a P-type lectin homodimer that directs newly synthesized lysosomal hydrolases from the Golgi complex to lysosomes via the mannose-6-phosphate sorting signal. Its more famous sibling, IGF2R (the cation-independent M6P receptor), doubles as a receptor for insulin-like growth factor II and has been directly implicated in angiotensin-II-driven cardiac hypertrophy. The cation-dependent isoform encoded by M6PR on chromosome 12p13 is expressed ubiquitously, with particularly high levels in immune and intestinal tissues, and participates in lysosomal enzyme sorting, receptor recycling, and endosomal trafficking. The rs1805762 variant sits in an intron of this gene and was identified in a genome-wide hypertension study in Japanese populations.

The Mechanism

rs1805762 is an intronic variant and does not alter the M6PR protein sequence directly. Its biological effect, if any, is likely regulatory — influencing splicing efficiency, isoform balance, or local enhancer activity within the M6PR locus on chromosome 12p13.31. The gene lies on the minus strand; on the plus strand, the variant is C→G. The G allele is the putative risk allele nominated by association evidence.

The connection to blood pressure is plausible through two distinct pathways. First, lysosomal trafficking integrity regulates degradation of vasoactive receptors, including angiotensin AT1 receptors — impaired lysosomal targeting could reduce receptor turnover and amplify angiotensin signaling. Second, the cation-independent M6PR (IGF2R) has been mechanistically linked to angiotensin-II-induced cardiac hypertrophy via the β-catenin/LEF1/IGF-IIR signaling axis22 β-catenin/LEF1/IGF-IIR signaling axis
Lai et al. IJMS 2019 — β-catenin activation upregulates IGF-IIR transcription through LEF1 binding sites in the promoter, driving downstream Gαq/PKC-α/ANP/BNP hypertrophic cascades. Whether the cation-dependent M6PR plays an analogous role is mechanistically possible but not yet established.

The Evidence

The primary evidence for rs1805762 comes from a high-density, three-tiered Japanese GWAS33 high-density, three-tiered Japanese GWAS
Kato et al. Hum Mol Genet 2008; 17(4):617-27 conducted as part of Japan's national hypertension genetics project. The study genotyped approximately 80,795 SNPs in Tier 1 (188 male hypertensive cases and 1,504 controls), refined to 2,676 candidates in Tier 2 (752 cases, 752 controls), and validated 75 SNPs in Tier 3 (619 cases, 1,406 controls). In the combined analysis, rs1805762 in M6PR reached P=0.0003 — not genome-wide significant by modern standards (5×10⁻⁸) but among the three strongest signals in the study, alongside ADD2 (P=1.7×10⁻⁵) and KIAA0789 (P=0.0001). The authors noted that independent replication would be required to confirm the finding.

Critically, this association was identified in a Japanese cohort where the G allele frequency is approximately 25% — far more common than in European (~2%) or African (<0.2%) populations. The variant has not been replicated in large-scale European or multi-ancestry GWAS, and it does not appear in the GWAS Catalog for any cardiovascular trait. The evidence level is therefore classified as emerging: biologically plausible, supported by a credible study, but without independent replication and with strong population stratification.

Practical Actions

For individuals of East Asian ancestry carrying one or two G alleles, the evidence is sufficient to warrant awareness and modest proactive monitoring, particularly if family history of hypertension is present. The intronic location means no drug effect is expected, and no nutrient metabolism changes are implicated. The most actionable step is periodic blood pressure tracking to detect early hypertensive trends that would justify lifestyle or medical management through established pathways.

For individuals of European, African, or South Asian ancestry, the G allele is extremely rare (less than 2%) and most carriers will be heterozygous. The population-level risk attributable to this variant in non-East-Asian individuals is negligible based on current evidence.

Interactions

rs1805762 was identified in the same study that nominated ADD2 (rs3755351) as the strongest hypertension signal (P=1.7×10⁻⁵). ADD2 (beta-adducin) regulates actin cytoskeleton assembly in red blood cells and renal tubule cells, affecting sodium transport. If M6PR's role in lysosomal receptor trafficking intersects with adducin-mediated sodium channel regulation — both ultimately affecting tubular sodium handling — combined risk from both loci would be biologically coherent, though no interaction study has tested this directly.

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal

Common M6PR genotype with no elevated hypertension risk from this variant

You carry two copies of the C allele at rs1805762 in the M6PR gene — the reference genotype found in approximately 90% of people globally and over 95% of Europeans and Africans. In the Japanese association study that nominated this variant, C/C homozygotes did not show elevated hypertension risk. This is the neutral genotype at this locus.

CG Intermediate

One copy of the M6PR G allele; modest hypertension association in East Asian populations

The M6PR gene encodes the cation-dependent mannose-6-phosphate receptor, a lysosomal sorting protein expressed in virtually all cell types. The rs1805762 intronic variant likely has a regulatory rather than coding effect — possibly influencing splicing or promoter activity. The biological connection to hypertension may involve lysosomal regulation of vasoactive receptor turnover or convergence with the IGF-IIR/M6PR signaling axis that has been linked to angiotensin-II-driven cardiac hypertrophy in cellular studies.

The evidence base is limited to a single study in Japanese participants. The variant has not been replicated in European or African cohorts, where the G allele is too rare to detect associations without very large sample sizes. Interpret this finding with appropriate caution — it is a biological lead, not a confirmed clinical risk factor.

GG High Risk

Two copies of the M6PR G allele; strongest hypertension association at this locus in East Asian populations

At the molecular level, M6PR governs lysosomal enzyme targeting through the mannose-6-phosphate sorting pathway. Disruption of this pathway could impair degradation of internalized vasoactive receptors (including angiotensin AT1R), potentially sustaining downstream blood pressure-elevating signaling. The closely related IGF2R (cation-independent M6P receptor) has been explicitly linked to angiotensin-II-induced cardiac hypertrophy through the β-catenin/LEF1/IGF-IIR axis, establishing biological precedent for M6P receptor involvement in hypertensive disease mechanisms.

Individuals with East Asian ancestry are most relevant to this finding. The G allele approaches 25% frequency in Japanese and Korean populations, making GG homozygosity a non-trivial genotype class there. The study's case-control design in a tier-validated three-stage analysis provides moderate confidence in the nominally significant finding, though genome-wide significance thresholds were not reached.